Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics

Viking Therapeutics, Inc. (VKTX): $2.71

-0.09 (-3.21%)

POWR Rating

Component Grades













VKTX Stock Price Chart Interactive Chart >

Price chart for VKTX

VKTX Price/Volume Stats

Current price $2.71 52-week high $7.20
Prev. close $2.80 52-week low $2.02
Day low $2.67 Volume 679,500
Day high $2.82 Avg. volume 1,119,661
50-day MA $2.37 Dividend yield N/A
200-day MA $4.10 Market Cap 209.68M

Viking Therapeutics, Inc. (VKTX) Company Bio

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.

VKTX Latest News Stream

Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream

Loading social stream, please wait...

View Full VKTX Social Stream

Latest VKTX News From Around the Web

Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

Maxim Group Thinks Viking Therapeutics’ Stock is Going to Recover

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $10.00. The company's shares closed last Thursday at $4.05, close to its 52-week low of $3.22. According to, Rahman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.2% and a 11.5% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Vertex Pharmaceuticals, and Galmed Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $19.

Howard Kim on TipRanks | February 11, 2022

3 Biotech Stocks That Are too Cheap to Ignore

The stock market is giving investors some real healthcare bargains right now. Patrick Bafuma (Intercept Pharma):  I will freely admit that Intercept Pharma has been a dog through the years, down a maddening 87% over the last five years. A significant portion of Intercept's drop was also due to a complete response letter in June 2020 for the treatment of non-alcoholic steatohepatitis (NASH).

Yahoo | February 10, 2022

Viking Therapeutics (VKTX) Q4 2021 Earnings Call Transcript

Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 9, 2022, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines, and milestones.

Yahoo | February 10, 2022

Viking Therapeutics GAAP EPS of -$0.16 beats by $0.03

Viking Therapeutics press release (NASDAQ:VKTX): Q4 GAAP EPS of -$0.16 beats by $0.03....

Seeking Alpha | February 9, 2022

Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments.

Yahoo | February 9, 2022

Read More 'VKTX' Stories Here

VKTX Price Returns

1-mo N/A
3-mo -9.67%
6-mo -41.09%
1-year -56.01%
3-year -67.35%
5-year 150.93%
YTD -41.09%
2021 -18.29%
2020 -29.80%
2019 4.84%
2018 88.42%
2017 241.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4645 seconds.